GlaxoSmithKline announced Financial Results for the period ended June 30, 2017.
The company’s Sales for the period increased by 25 percent in the outgoing year, whereas the Total Profit after Taxation for the Period increased by 33 percent.
The board has recommended no Cash Dividend, any bonus or right shares.
Comparison of Key Financials
Unconsolidated Profit and Loss Account – For the Six Months Ended |
|||
Key Financials |
Jan – June, 2017 |
Jan – Jun, 2016 |
% Change |
Amounts in PKR ‘000 |
|||
Sales |
16,208,185 |
12,916,465 |
25% |
Cost of Sales |
11,824,067 |
9,510,709 |
24% |
Gross Profit |
4,384,118 |
3,405,756 |
29% |
Selling, Marketing and Dist: Expenses |
1,478,058 |
1,355,368 |
9% |
Admin: Expenses |
482,952 |
490,813 |
-2% |
Other Operating Expenses |
222,013 |
137,921 |
61% |
Other Income |
294,599 |
196,516 |
50% |
Profit from Operations |
2,495,694 |
1,618,170 |
54% |
Finance Cost |
9,761 |
8,598 |
14% |
Profit before Taxation |
2,485,933 |
1,609,752 |
54% |
Taxation |
1,027,937 |
675,049 |
52% |
Profit after Taxation from Continued Operations |
1,457,996 |
934,523 |
56% |
(Loss)/Profit after Taxation from dis-continued Operations |
(31,721) |
138,816 |
-123% |
Total Profit after Operations |
1,426,275 |
1,073,339 |
33% |
EPS – Continued Operations |
4.58 |
2.93 |
56% |
EPS – Discontinued Operations |
(0.10) |
0.44 |
-123% |
EPS |
4.48 |
3.37 |
33% |
Company release on Earnings Report can be accessed here.